Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 11;20(7):e0327746.
doi: 10.1371/journal.pone.0327746. eCollection 2025.

Association between self-administrated prophylactics and SARS-CoV-2 infection among traditional market vendors from the Central Highlands of Peru: A nested case-control study

Affiliations

Association between self-administrated prophylactics and SARS-CoV-2 infection among traditional market vendors from the Central Highlands of Peru: A nested case-control study

Daniel A Andrade et al. PLoS One. .

Abstract

Although COVID-19 is no longer a public health emergency of international concern, understanding behaviours such as self-medication remains relevant for informing future outbreak responses and improving public health preparedness. Despite its widespread use during the pandemic, research on medications preventing SARS-CoV-2 infection in healthy individuals is scarce. We investigated the association between self-administered prophylactics and SARS-CoV-2 infection during the third wave of the pandemic in Peru. A nested case-control study was carried out in a cohort of traditional market vendors in the Peruvian Central Highlands, enrolled in a health program. Cases (positive SARS-CoV-2 diagnosis) were matched with controls (negative) by age, sex, and market of origin. Conditional logistic regression models were fitted to evaluate the association between self-administered prophylactics and SARS-CoV-2 infection. As a result, 73 cases were matched with 176 controls. Acetylsalicylic acid consumption increased SARS-CoV-2 infection odds (adjusted Odds Ratio 2.34; 95% Confidence Interval 1.17-4.66). Conversely, vitamin C consumption reduced infection odds (adjusted Odds Ratio 0.44; 95% Confidence Interval 0.23-0.87). Finally, not having the COVID-19 booster increased infection odds (adjusted Odds Ratio 3.38; 95% Confidence Interval 1.43-7.95). In conclusion, our findings suggest that acetylsalicylic acid consumption increased the odds of SARS-CoV-2 infection, whereas vitamin C consumption decreased the infection odds during the third epidemic wave in Peru. Further research on the use of these medications is needed to establish a robust causal relationship with SARS-CoV-2 infection.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Map of the province of Huancayo.
The main map presents the streets (dark grey lines) and points the studied wet markets (red dots) and laboratories (blue dots). The map of the Junin region presents the provinces of Huancayo (green) and Jauja (yellow), while the map of Peru presents the Junin region (dark grey). These maps were created using public domain basemaps provided by the “Instituto Nacional de Estadística e Informática” (https://ide.inei.gob.pe/) and the “Infraestructura de Datos Espaciales del Perú” (https://www.idep.gob.pe/).
Fig 2
Fig 2. Flowchart of the number of participants at each phase of the program.
Fig 3
Fig 3. Distribution of participants by variables presenting the main effects of the analysis.
Fig 4
Fig 4. Predicted probabilities calculated through the adjusted conditional logistic regression model.
The x axis represents the COVID-19 booster dose and y axis the predicted odds of a positive SARS-CoV-2 diagnosis. Lines represent participants with (blue) or without (red) acetylsalicylic acid consumption. Columns represent the categorization by vitamin C consumption. The lowest risk of positive test result is observed in the group with booster dose, no consumption of acetylsalicylic acid and consumption of vitamin C.

References

    1. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med. 2023;388(2):183–5. doi: 10.1056/NEJMc2214293 - DOI - PMC - PubMed
    1. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613(7942):130–7. doi: 10.1038/s41586-022-05522-2 - DOI - PMC - PubMed
    1. Toyama M, Vargas L, Ticlihuanca S, Quispe AM. Regional clustering and waves patterns due to COVID-19 by the index virus and the lambda/gamma, and delta/omicron SARS-CoV-2 variants in Peru. Annals of Epidemiology. 2022;75:74–5. doi: 10.1016/j.annepidem.2022.08.026 - DOI - PMC - PubMed
    1. Liu Y, Zhao S, Yang L, Aliaga-Linares L, He D. All-cause mortality during the COVID-19 pandemic in Peru. IJID Reg. 2022;5:177–9. doi: 10.1016/j.ijregi.2022.10.005 - DOI - PMC - PubMed
    1. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Pacientes post-vacunas hospitalizados y estado vacunal. In: Tablero de hospitalizados y vacunas. Accessed 2023 December 3 https://www.dge.gob.pe/dashhospitalizadosvacunas/#grafico04